NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/26/2023
Back to search
Official data from USPTO
EIRGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
EIRGEN
ST13
US500000097383276Class
1, 5, 42
Filing
97383276
Registration
7172805
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
09/26/2023
Trademark type
Word
Nice classes
1, 5, 42
Filing date
04/26/2022
Registration date
09/26/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/26/2023
Last transaction
09/26/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
Waterford, IE
Examiner
MAJCHER HARTNETT, MEGAN
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
EirGen Pharma Limited
Representatives
Sean P. McMahon SEAN P. MCMAHON, PLLC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in industryscience and photography; chemical substances for preserving foodstuffs; adhesives used in industry; biological preparations for use in biotechnology other than for medical use
Class 5
Pharmaceutical preparations and substances for the treatment of medical ailments and medical conditionscardiovascular and central nervous system disordersmalignant diseases and immunosuppressionmusculoskeletal and joint diseasesoculargynecological and urinary tract disorders and infectious and non-infectious diseases; sanitary preparations for medical use; prescription pharmaceutical and biotechnological preparations for the treatment of medical ailments and medical conditionscardiovascular and central nervous system disordersmalignant diseases and immunosuppression musculoskeletal and joint diseasesoculargynecological and urinary tract disorders and infectious and non-infectious diseases; biological preparations for medical purposesfor use in biotechnology for the treatment of cancerinfectious diseasesmetabolic diseases and disorders; chemical preparations and reagents for use in biotechnology for medical and veterinary userenal diseases and disorderscognitive and neurological disordersvitamin D insufficienciescancer and infectious diseases; injectable solutions for medical purposesinjectable pharmaceuticals for cardiovascular and central nervous system disordersmalignant diseases and immunosuppressionmusculoskeletal and joint diseasesoculargynecological and urinary tract disorders; dietetic foodspastacrackersbreadfood supplementsinfusionsdrinks and beverages all adapted for medical use; all purpose disinfectantsoral disinfectants for medical and hygienic purposesdisinfectants for hygienic and sanitary purposesdisinfectants for medical instruments; syrups for pharmaceutical purposescough syrups; vaccines; syringes containing pharmaceuticals for the treatment of cardiovascular and central nervous system disordersmalignant diseases and immunosuppressionmusculoskeletal and joint diseasesoculargynecological and urinary tract disorders for medical use; pre-filled disposable syringes and hypodermic syringes containing pharmaceuticals for the treatment of cardiovascular and central nervous system disordersmalignant diseases and immunosuppressionmusculoskeletal and joint diseasesoculargynecological and urinary tract disorders for medical use
Class 42
The provision of information on the subject of research and developmentdrug development and product evaluation all in the field of pharmaceuticals and biotechnology; scientific and industrial research relating to pharmaceuticals and biotechnology
Publications
History of USPTO decisions and trademark events.
19 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/26/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/11/2023
PUBO
PUBLISHED FOR OPPOSITION
07/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/21/2023
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
06/07/2023
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
06/02/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/30/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/26/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/25/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/25/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
05/15/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
05/15/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/13/2023
GNRT
NON-FINAL ACTION E-MAILED
02/13/2023
CNRT
NON-FINAL ACTION WRITTEN
02/13/2023
DOCK
ASSIGNED TO EXAMINER
02/13/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/03/2022
NWAP
NEW APPLICATION ENTERED
04/29/2022
Continuous trademark protection
Get notified about every new filing that threatens EIRGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.